Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab

David A Bond
Lapo Alinari
Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Abstract: Classical Hodgkin’s lymphoma (cHL) is a B-cell malignancy comprised of pathologic Reed Sternberg cells with a surrounding immune-tolerant inflammatory milieu. RS cells evade immune recognition in part through programmed death ligand 1 (PD-L1) overexpression, which is genetically programmed through copy number alterations, polysomy, and amplification of the 9p24.1 locus encoding PD-L1. By engaging with PD-1+ T-cells, PD-L1 delivers a potent immune suppressive signal promoting immunologic escape of the tumor cell. Enhancing antitumor immune response by targeting PD-1 with the monoclonal antibody nivolumab has proved to be effective in multiple solid tumors, but the highest response rates to date have been reported in patients with cHL, with over 65% of treated patients achieving an objective clinical response. In this review, we will summarize the published evidence regarding the activity of nivolumab in cHL as well as its current place in therapy. We will review the pharmacology, mechanism of action, and side effects of nivolumab as well as the emerging data indicating possible increased risk of graft versus host disease in patients treated with PD-1 inhibitors either pre- or post-allogeneic stem cell transplant. Given the remarkable single-agent activity and safety profile of PD-1 inhibitors in heavily pretreated patients with cHL, the possibility of employing nivolumab in combination with other active agents and earlier in therapy is a promising area of active investigation, and we will briefly summarize current clinical trials.

Keywords: nivolumab, Hodgkin’s lymphoma, pembrolizumab, checkpoint inhibitor therapy

Relapsed/refractory classical Hodgkin’s lymphoma

Classical Hodgkin’s lymphoma (cHL) is a lymphoid malignancy characterized by a small percentage of pathologic Reed Sternberg (RS) cells within a robust nodal inflammatory environment. Standard options for frontline therapy for patients with cHL depend upon stage and risk factors at diagnosis, and consist of combination chemotherapy with or without radiation therapy.1,2 Acceptable frontline chemotherapy regimens for cHL include adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), Stanford V, as well as escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) for patients with advanced stage disease and high risk international prognostic score.3–9 For patients with favorable risk early-stage cHL, treatment with ABVD with or without radiation therapy is associated with 5-year progression-free survival (PFS) of ≥90%.10,11 For unfavorable risk or bulky early-stage disease, 5 year failure-free survival rates of 85% and 79% are reported with ABVD + radiation therapy and Stanford V, respectively.12 In patients with high-risk stage III/IV disease, frontline treatment with 6–8 cycles of ABVD leads to 5 years PFS rates ranging from 68% to 73%, while escalated BEACOPP has been
For patients with relapsed/refractory disease after initial therapy, standard treatment includes salvage chemotherapy followed by autologous stem cell transplant (ASCT). With ASCT, 5-year PFS rates of 50%–60% can be achieved in patients with relapsed chemosensitive disease, compared with 5-year PFS rates of 40%–45% for patients with primary refractory disease. For patients with relapsed/refractory disease following ASCT, the anti-CD30 monoclonal antibody drug conjugate brentuximab vedotin (BV) (Adcetris, Seattle Genetics, Bothell, WA, USA) demonstrated an overall response rate (ORR) of 75%, including complete response (CR) rate of 36% with a median PFS of 9.3 months in a pivotal phase II trial, leading to US Food and Drug Administration (FDA) approval in this setting.

In the phase III AETHERA trial, BV consolidation after ASCT resulted in an improvement in PFS (43 vs 24 months) compared with placebo in patients at high risk for relapse.

Although there are multiple treatment options available for patients who fail ASCT and BV, historical median overall survival (OS) for these patients is about 2 years. Allogeneic stem cell transplant (SCT) remains the only known curative option for this patient population, with the presence of a graft versus lymphoma effect suggested by indirect evidence such as lower relapse rates in patients that develop chronic graft-versus-host disease (GVHD). However, despite potential for durable remissions, the historical 5-year PFS has been about 20% with a 5-year OS of 30%. For patients who are candidates for allogeneic SCT and desire this approach, combination chemotherapy may be used for maximal disease reduction prior to transplant, albeit at the cost of significant treatment-associated toxicities. Asymptomatic patients may be observed for a period of time or treated with radiation therapy in case of localized relapse. Palliative single-agent chemotherapy options include gemcitabine, vinorelbine, vinblastine, bendamustine, liposomal doxorubicin, or biological agents such as lenalidomide, the histone deacetylase inhibitors vorinostat and panobinostat, or the mammalian target of rapamycin inhibitor everolimus. While there are many available options for therapy, responses are not durable, and new treatments are needed for patients with relapse following ASCT and BV.

RS cells avoid antitumor immune response by release of immunosuppressive cytokines such as interferon-gamma, TGF β, chemokine ligands 17 (CCL17) and 22 (CCL22), and interleukin 10 (IL-10) as well as expression of immune-tolerance-inducing surface molecules. The identification that two of these immunomodulatory surface proteins, PD-L1 (B7H1) and PD-L2 (B7DC), that are expressed by RS cells, provided the rationale for therapeutic targeting of their corresponding T-cell target, the receptor programmed death 1 (PD-1, CD279). As will be discussed in this review, PD-1 inhibition with the monoclonal antibodies nivolumab and pembrolizumab have emerged as a viable treatment option for patients with cHL after ASCT failure. In this review, we will summarize the mechanism of action, pharmacology, and side effects of nivolumab, the role of PD-1 signaling in cHL, published results to date regarding treatment of cHL with nivolumab, the current role for nivolumab in the treatment of cHL, and future areas of research including ongoing trials in cHL with nivolumab and other PD-1 inhibitors.

**PD-1/PD-L signaling**

PD-1 is a coinhibitory receptor of the CD28 superfamily expressed on T-cells. By interacting with its corresponding ligands (PD-L1 and PD-L2) on antigen-presenting cells (APCs), PD-1 attenuates T-cell response and promotes T-cell tolerance by inhibiting cytokine production and T-cell proliferation via suppression of Src Homology Phosphatase 2 (SHP-2) signaling within the T-cell (Figure 1). In a healthy host, PD-1 expression is increased in activated T-cells to counter-regulate immune response to infection to prevent autoimmunity. In addition to PD-1, PD-L1 has also been shown to competitively engage CD80 (CD28 ligand), decreasing the stimulatory signal mediated by the CD80/CD28 interaction and further inhibiting T-cell proliferation and function. The identification of these ligands was followed by the discovery that PD-L1 can also be expressed on tumor cells to evade antitumor immune response. PD-L2 expression by tumors is less extensively reported, but has relevance for cHL as well as the closely related disease primary mediastinal B cell lymphoma, where it appears to be overexpressed by tumor cells due to gene amplification.

Gain in chromosome 9p was first observed in primary mediastinal B-cell lymphoma specimens and later discovered in RS cells, distinguishing these diseases genetically from other B cell lymphomas. Via high-density single-nucleotide polymorphism arrays, the 9p24.1 amplicon was shown to contain _CD274_, which encodes PD-L1, and _PDCD1LG2_, which encodes PD-L2, as well as Janus Kinase...
2 (JAK2), which has been shown to upregulate PD-L1 and PD-L2 expression via the STAT signaling pathway. This finding provided a genetic basis for the increased PD-L1 and PD-L2 expression in RS cells and suggested the importance of PD-1 signaling leading to immune evasion in this disease. Increased PD-L1 and PD-L2 expression in RS cells has also been shown to be mediated by the CTIIA gene fusion as well as by Epstein–Barr virus (EBV) infection. Subsequent analyses of RS cells isolated from biopsy specimens in cohorts of patients with both newly diagnosed and relapsed/refractory cHL have shown almost universal genetic modification of the PD-L1 and PD-L2 loci via either polysomy of 9p or copy gain or amplification of 9p24.1. In a cohort of 108 patients with newly diagnosed cHL treated with the Stanford V regimen, amplification of 9p24.1 was associated with advanced-stage disease and shorter PFS compared with polysomy or copy gain, suggesting that increased amplification of PD-L1 and PD-L2 may mediate a more aggressive clinical course.

cHL is characterized by a small percentage of PD-L1+ RS cells within a robust but ineffective inflammatory and immune environment that includes PD-1 expressing T-cells. This body of evidence, suggesting the importance of PD-L1 and PD-L2 signaling as a common pathway for immune evasion in cHL, provides the rationale for PD-1 targeting in cHL.

**Introduction to nivolumab pharmacology, mode of action, and pharmacokinetics**

Nivolumab (Opdivo, formerly BMS-936558 and MDX-1106; Bristol-Myers Squibb, New York, NY, USA) is a fully human monoclonal IgG4 antibody targeting PD-1. Initial studies of the safety and activity of nivolumab were performed in patients with advanced melanoma, castration resistant prostate cancer, non-small-cell lung cancer (NSCLC), renal-cell cancer (RCC), and colorectal cancer, demonstrating an acceptable safety profile and response rates ranging from 18%–28% in melanoma, NSCLC, and RCC, including durable response in a significant proportion of responders. In these initial studies, nivolumab was given at 14 day-intervals with doses escalated from 0.1 mg/kg, 1 mg/kg to 3 mg/kg, and 10 mg/kg with no maximum tolerated dose determined. A peak concentration of antibody was seen 1–4 hours after infusion, and while there was a linear correlation between dose, serum concentration, and area

---

**Figure 1** This figure depicts PD-L1 and PD-L2 signaling between an RS cell and a T-cell within the tumor microenvironment. Notes: In addition to acting as a ligand for PD-1 leading to inhibitory signaling through suppression of SHP-2, PD-L1 also acts as a receptor for CD 80 on antigen presenting cells, thereby inhibiting binding of CD 80 with CD 28 on T cells. PD-1 inhibitors bind PD-1, thus attenuating PD-1 mediated T-cell exhaustion. **Abbreviations:** PD-1, programmed death 1; PD-L1, programmed death ligand 1; PD-L2, programmed death ligand 2; RS, Reed Sternberg cell; SHP-2, Src homology phosphotase 2.
under the curve at doses ranging from 0.1 to 10 mg/kg, the PD-1 receptor occupancy of peripheral blood mononuclear cells was similar at all dose levels in 65 melanoma patients (median of 64% at 0.1 mg/kg, median of 70% at 10 mg/kg). Objective response rates were numerically similar at all dose levels for patients with melanoma and RCC. However, in NSCLC, all responses in the Phase I study were seen at a dose level of ≥3 mg/kg, with none of the 17 patients treated with the 1 mg/kg dose level achieving objective response. A subset of tumor samples was examined for PD-L1 expression by immunohistochemistry, and preliminary data suggested a correlation between PD-L1 expression on tumor cells and response to PD-1 blockade.

Subsequent studies in melanoma, RCC, and NSCLC utilizing nivolumab at a dose of 3 mg/kg every 2 weeks validated its clinical activity in these diseases, leading to respective FDA approvals as second-line therapy. In studies to date, the dose response rate and adverse event (AE) rate for nivolumab appears relatively flat through a wide range of doses, and the FDA cited this lack of apparent dose–response relation when changing the approved dose of nivolumab monotherapy for NSCLC, RCC, and melanoma to a non-weight-based dose of 240 mg every 2 weeks. Studies to date of nivolumab as monotherapy for cHL, discussed in greater detail later, have utilized a dose of 3 mg/kg given every 2 weeks, which remains the FDA approved dose for this disease.

Pharmacokinetic studies of 909 patients with different types of solid tumors and hematologic malignancies treated with nivolumab showed an elimination half-life of 26.7 days, mean time to steady state concentration of 12 weeks, and volume of distribution at steady state of 8.0 L. Among 1,086 patients treated on 4 clinical trials of nivolumab for multiple solid tumor types, the presence of antidrug antibodies was detected in a minority of patients. This did not appear to lead to clinically meaningful loss of response, hypersensitivity reactions, or accelerated drug clearance.

**Activity of nivolumab in cHL**

The initial evidence for the activity of nivolumab in patients with cHL comes from a phase I study of 23 patients with relapsed/refractory cHL and a phase II study of 80 patients with relapsed and refractory disease and prior treatment with both BV and ASCT (Table 1). The genetic basis of PD-L1 expression in cHL with consequent T-cell exhaustion provided the rationale to include 23 patients with relapsed/refractory cHL as a cohort-expansion group in a phase I dose-escalation trial of single-agent nivolumab in patients with relapsed/refractory hematologic malignancies. Patients were treated with nivolumab 3 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or complete response. Of the cHL patients included, 15/23 had received at least 4 prior lines of therapy, 78% had been previously treated with BV, and 78% had previously undergone ASCT. ORR was 87%; CRs were reported in 4 patients at time of initial publication, and 2 additional patients achieved a CR when extended follow-up was later reported at the 2015 American Society of Hematology (ASH) annual meeting. With extended follow-up, while 10 patients were found to have durable responses to treatment, 4 of the 20 responding patients eventually developed progressive disease, 5 discontinued nivolumab while in response in order to undergo SCT (allogeneic in 4, ASCT in 1), and 1 patient discontinued nivolumab due to toxicity with response maintained off of nivolumab at 120 days follow-up. In 2 of the responding patients, CR was maintained at 40 weeks after discontinuation of treatment. One patient with CR relapsed 43 weeks after cessation of nivolumab, but was able to again achieve CR when retreated with nivolumab. At the time of extended follow-up, 5 patients continued to receive nivolumab at ≥82 weeks of therapy.

Recently, the results of a multicenter, multicohort, phase II trial of nivolumab for cHL patients after failure of both ASCT and BV were reported. Eighty patients enrolled across 34 medical centers in North America and Europe were treated with nivolumab every 2 weeks at a dose of 3 mg/kg and continued until unacceptable toxicity, progression, death, or withdrawal from the study. Eligible patients were required to have previously undergone ASCT followed by BV but were not required to be BV refractory. The median patient age was 37, 64% were males, and about half (49%) had received at least five prior lines of therapy. Forty three (54%) patients were refractory to BV, and 6 (8%) had received more than one prior line of BV. The ORR was 66% after review by independent radiological review committee, with 9% of patients achieving CR as defined by independent radiological review committee. The investigator-assessed ORR was similar (58%), with a higher assessment (28%) of patients deemed to have achieved CR. Of the 43 patients refractory to most recent treatment with BV, 31 (72%) responded to nivolumab. Responses were seen at a median of 2.1 months from the start of treatment, although 22 of the 58 patients responding to treatment did not demonstrate response on initial follow-up scans 9 weeks after the start of treatment. At 6 months, the PFS was 77%. Updated results with a minimum of 12 months of follow-up (median follow-up 15.4 months) were presented at the 2016 ASH annual meeting with a median

**Table 1. Characteristics of patients included in the phase I trial and the cohort expansion of nivolumab in relapsed-refractory cHL.**

| Characteristics | Phase I | Cohort Expansion |
|----------------|---------|------------------|
| Dose level (mg/kg) | 3 | 3 |
| Number of patients | 23 | 15 |
| Prior treatments | ≥3 | ≥3 |
| ORR | 87% | 87% |
| CR | 4 | 2 |
| Relapse after response | 5 | 2 |
| Total duration of treatment (months) | 12 | 40 |
| ORR at 12 weeks follow-up | 66% | 66% |
| CR rate at 12 weeks follow-up | 54% | 54% |
| Patients refractory to BV | 43 | 31 |
| Patients refractory to ASCT | 31 | 22 |
| Patients refractory to prior treatment | 58 | 58 |
| Median age (years) | 37 | 37 |
| Gender distribution | 64% male | 64% male |
| Prior ASCT | 78% | 78% |
| Prior BV | 78% | 78% |
| Prior SCT | 22% | 22% |
| Prior withdrawal from study | 8% | 8% |
| Median time to CR (months) | 2.1 | 2.1 |
| Median time to PFS (months) | 6 | 6 |
| Median time to progression (months) | 6 | 6 |

**Table 2. Median reaction time, duration of treatment, and time to response for patients included in the phase II trial of nivolumab in relapsed-refractory cHL.**

| Characteristics | Median Reaction Time (months) | Duration of Treatment (months) | Time to Response (months) |
|----------------|-----------------------------|------------------------------|----------------------------|
| ORR | 6 | 12 | 12 |
| CR | 6 | 15.4 | 15.4 |
| Patients refractory to BV | 4.5 | 15.4 | 15.4 |
| Patients refractory to ASCT | 4.5 | 15.4 | 15.4 |
| Patients refractory to prior treatment | 4.5 | 15.4 | 15.4 |

**Table 3. Median reaction time, duration of treatment, and time to response for patients included in the phase II trial of nivolumab in relapsed-refractory cHL.**

| Characteristics | Median Reaction Time (months) | Duration of Treatment (months) | Time to Response (months) |
|----------------|-----------------------------|------------------------------|----------------------------|
| ORR | 6 | 12 | 12 |
| CR | 6 | 15.4 | 15.4 |
| Patients refractory to BV | 4.5 | 15.4 | 15.4 |
| Patients refractory to ASCT | 4.5 | 15.4 | 15.4 |
| Patients refractory to prior treatment | 4.5 | 15.4 | 15.4 |

**Table 4. Median reaction time, duration of treatment, and time to response for patients included in the phase II trial of nivolumab in relapsed-refractory cHL.**

| Characteristics | Median Reaction Time (months) | Duration of Treatment (months) | Time to Response (months) |
|----------------|-----------------------------|------------------------------|----------------------------|
| ORR | 6 | 12 | 12 |
| CR | 6 | 15.4 | 15.4 |
| Patients refractory to BV | 4.5 | 15.4 | 15.4 |
| Patients refractory to ASCT | 4.5 | 15.4 | 15.4 |
| Patients refractory to prior treatment | 4.5 | 15.4 | 15.4 |
ASCT and posttransplantation BV of patients with cHL that has relapsed or progressed after granted accelerated approval to nivolumab for the treatment discontinued therapy due to AEs.77 At updated follow-up, 37 (46%) patients had discontinued therapy, including 19 (24%) due to disease progression, 7 (9%) who proceeded to allogeneic SCT, and 5 (6%) who discontinued therapy due to autoimmunity and, as could be anticipated, patients with grade 3 or 4 events seen in 12 (52%) patients.64 The most common adverse effects attributed to treatment were rash (22%), thrombocytopenia (17%), pyrexia (13%), diarrhea (13%), nausea (13%), pruritus (13%), and fatigue (13%).64 Two patients experienced grade 3 AEs were believed to be drug related, acute pancreatitis and myelodysplastic syndrome in 1 patient each.64 The patient with myelodysplastic syndrome in 1 patient each.64 The patient with myelodysplastic syndrome was heavily pretreated with 6 lines of prior chemotherapy, radiation therapy, and ASCT. Newly diagnosed hypothyroidism was reported in 2 (9%) patients, and no other autoimmune endocrine toxicities were noted.

| Table 1 Summary of published trials of PD-1 inhibitors for cHL |
|---------------------------------------------------------------|
| Variable | Ansell et al64 | Younes et al65 | Armand et al91 | Moskowitz et al92 |
| PD-1 inhibitor | Nivolumab | Nivolumab | Pembrolizumab | Pembrolizumab |
| Number of patients | 23 | 80 | 31 | 210a |
| Prior BV tx | 78% | 100% | 100% | 83%a |
| Prior ASCT | 78% | 100% | 71% | 61%a |
| Overall Response Rate | 87% | 66% | 65% | 68% |
| CR | 17% | 9% | 16% | 22% |
| PR | 70% | 58% | 48% | 46% |
| PFS at specified timepoint | 86% 24 weeks | 77% 6 months | 69% 24 weeks, 46% 52 weeks | NR |
| Subsequent autologous-SCT | 22% | 6% | 10% | NR |

Notes: *Includes 3 cohorts as described in text. **Abbreviations: BV tx, brentuximab vedotin therapy; ASCT, autologous stem cell transplant; cHL, classical Hodgkin’s lymphoma; CR, complete response; PD-1, programmed death 1; PR, partial response; PFS, progression free survival; allo SCT, allogenic stem cell transplant; NR, not reported.

PFS of 14.8 months, median duration of partial response (PR) of 13.1 months, and median duration of CR not reached.77 At updated follow-up, 37 (46%) patients had discontinued therapy, including 19 (24%) due to disease progression, 7 (9%) who proceeded to allogeneic SCT, and 5 (6%) who discontinued therapy due to AEs.77

Consistent with the immune-mediated mechanism of action of nivolumab, delayed responses were seen, including 1 patient with appearance of a new lesion at week 9 of therapy who went on to have 2 subsequent negative positron emission tomography scans at weeks 25 and 33.65 By protocol definition, this patient’s best response was defined as progressive disease despite the subsequent response to treatment. Given the pattern of late response and benefit beyond traditionally defined progression, the trial was amended to allow patients to continue nivolumab beyond progression at the investigator’s discretion. Of 9 patients who continued nivolumab beyond progression, 5 maintained reduction in total tumor volume.65 In an exploratory post hoc analysis, higher PD-L1 expression was associated with improved best overall response, but the majority of patients achieved at least PR even in the lowest quartile of PD-L1 expression.65 Based on the results of this trial, on May 17, 2016, the FDA granted accelerated approval to nivolumab for the treatment of patients with cHL that has relapsed or progressed after ASCT and posttransplantation BV.

Safety and tolerability

To date, experience with nivolumab in both cHL and other malignancies shows a unique but acceptable toxicity profile compared with conventional chemotherapy (Table 2). PD-1 functions to attenuate immune response in order to prevent autoimmunity and, as could be anticipated, patients treated with nivolumab have demonstrated autoimmune reactions following treatment, termed immune-related AEs (IRAEs).78 These IRAEs include acute hepatitis, colitis, dermatitis, pneumonitis, pancreatitis, and autoimmune endocrine disorders, including hypophysitis and immune-related thyroid disease.74,79,80 The combination of nivolumab with other immune checkpoint inhibitors such as the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) monoclonal antibody ipilimumab has been associated with more frequent incidence of high grade IRAE, but serious adverse effects are also seen in a minority of patients treated with single-agent nivolumab, leading to drug discontinuation in about 5% of cases.67,81 Grade 3–4 IRAEs are most often treated initially with corticosteroid therapy; TNF inhibitors or other immunosuppressant therapy appears to be effective in some steroid refractory cases.74 The management of these autoimmune toxicities is reviewed in detail separately.74,78,82

While the side effects seen with PD-1 inhibitors have been similar across disease groups, there has been a suggestion of a higher incidence of hematologic toxicities in patients with lymphoma compared to those with solid organ malignancies.83 The reason for this disparity is unclear, but may be in part due to the heavy pretreatment of the patients with lymphoma included in early studies.

In the first published study of nivolumab for the treatment of cHL, AEs of any grade were observed in 22 of 23 patients, with grade 3 or 4 events seen in 12 (52%) patients.64 The most common adverse effects attributed to treatment were rash (22%), thrombocytopenia (17%), pyrexia (13%), diarrhea (13%), nausea (13%), pruritus (13%), and fatigue (13%).64 Two patients experienced grade 3 AEs were believed to be drug related, acute pancreatitis and myelodysplastic syndrome in 1 patient each.64 The patient with myelodysplastic syndrome was heavily pretreated with 6 lines of prior chemotherapy, radiation therapy, and ASCT. Newly diagnosed hypothyroidism was reported in 2 (9%) patients, and no other autoimmune endocrine toxicities were noted.
Grade 1 hypersensitivity infusion reactions were noted in 2 patients (9%) not requiring treatment discontinuation. There were no deaths due to toxicity and no grade 4 AEs attributed to nivolumab.64 In the landmark phase II study of 80 patients with relapsed or refractory cHL following ASCT and BV treated with nivolumab, 71 (89%) patients had a reported treatment-related AE of any grade.65 The most commonly reported treatment-related AEs were fatigue (25%), infusion-related reaction (20%), rash (15%), pyrexia (14%), arthralgia (14%), and diarrhea (10%).65 Grade 3 AEs were reported in 17 (21%) patients, and 3 patients had reported grade 4 events (4%). Drug-related grade 3 AEs included neutropenia (5%), increased lipase (3%), increased AST/ALT (3%), abdominal pain (3%), and rash (1%).65 Two patients discontinued treatment due to AEs believed to be drug related; 1 patient with newly diagnosed autoimmune hepatitis, and 1 patient with increased AST/ALT. One patient died from multiorgan failure and was found on autopsy to have a new diagnosis of EBV-positive T-cell lymphoma, believed to be unrelated to nivolumab therapy.65 Pneumonitis was seen in 2 patients (1 with grade 2 and the other with grade 3), which was responsive to corticosteroids in both cases. The patient with grade 3 pneumonitis had already discontinued nivolumab due to grade 3 autoimmune hepatitis diagnosed prior to the onset of pneumonitis.65 Most cHL patients are treated with agents with potential lung toxicity including bleomycin, radiation therapy, and BV, and therefore may be at an increased risk for pulmonary toxicity or pneumonitis. Despite the side effects associated with PD-1 blockade, nivolumab is relatively well tolerated overall and generally associated with fewer high-grade side effects when compared with conventional chemotherapy.89

**Table 2** Summary of common and serious AEs reported with nivolumab

| Common therapy-related AEs | Incidence | Serious therapy-related AEs | Incidence |
|----------------------------|-----------|-----------------------------|----------|
| Rash                       | 15%–22%   | Neutropenia                 | 5%       |
| Fatigue                    | 13%–25%   | Elevated AST/ALT            | 3%       |
| Infusion Reaction          | 9%–20%    | Elevated Lipase             | 3%       |
| Pyrexia                    | 13%–14%   | Pneumonitis                 | 3%       |
| Arthralgia                 | 14%       | Autoimmune hepatitis        | 1%       |
| Nausea                     | 13%       |                             |          |
| Diarrhea                   | 10%–13%   |                             |          |
| Hypothyroidism             | 9%        |                             |          |
| Thrombocytopenia           | 1%–17%    |                             |          |

**Abbreviation:** AEs, adverse events.

commonly observed with PD-1 inhibitors than with CTLA-4 inhibitors, providers should be aware of the potential for autoimmune hypophysitis with checkpoint inhibition and be alert to signs and symptoms of adrenal insufficiency or central hypothyroidism.98 New-onset type 1 diabetes mellitus has been reported in at least 1 instance in a patient with cHL treated with nivolumab.64 While rare and not yet reported in patients with cHL treated with nivolumab, it is worthwhile for the clinician to be aware of the potential for life-threatening myocarditis, rhabdomyolysis, neurologic disorders including myasthenia gravis and Guillain-Barré syndrome, and skin reactions including Stevens–Johnson syndrome, bullous pemphigoid, and toxic epidermal necrolysis, which have been seen in patients following checkpoint blockade.80,82,85–88 Despite the side effects associated with PD-1 blockade, nivolumab is relatively well tolerated overall and generally associated with fewer high-grade side effects when compared with conventional chemotherapy.89

**Other PD-1 blocking agents, pembrolizumab**

Pembrolizumab (Keytruda, formerly lambrolizumab and MK-3475, Merck Oncology, Kenilworth, NJ, USA) is a humanized monoclonal IgG4 antibody also targeting PD-1. Pembrolizumab has a higher reported affinity for PD-1, but whether this is clinically meaningful remains unclear given the wide therapeutic range seen with PD-1 inhibitors.90 In the Phase 1b KEYNOTE 013 trial, 31 patients with relapsed/refractory cHL were treated with pembrolizumab at a dose of 10 mg/kg every 2 weeks.91 The patients enrolled were heavily pretreated, with over half (55%) having received at least 5 prior lines of therapy. The majority (77%) of patients had previously undergone ASCT and, by design, all patients had failed BV, including 18 (58%) patients with BV-refractory disease. Of the 31 patients, 5 (16%) patients achieved a CR and 15 (48%) patients...
attained a PR for an ORR of 65%. The responses achieved appeared to be durable in many patients, with a PFS rate of 46% at 1 year. Treatment-related AEs were reported in 68% of patients including hypothyroidism (16%), diarrhea (16%), and pneumonitis (10%). Two patients were taken off therapy due to AEs; 1 with grade 2 pneumonitis and 1 with grade 3 nephrotic syndrome, both of whom responded to treatment with corticosteroids after discontinuation of pembrolizumab.95 Grade 3 AEs not requiring treatment discontinuation were reported in 4 patients including colitis, joint swelling, back pain, axillary pain, and elevated liver aminotransferase levels.

In the phase 2 KEYNOTE-087 trial (NCT 02453594), 210 patients with relapsed/refractory cHL were enrolled across 3 cohorts, including patients with relapsed/refractory disease after ASCT and subsequent treatment with BV (cohort 1), patients ineligible for ASCT due chemo-resistant disease and BV therapy failure (cohort 2), and patients with prior ASCT without subsequent BV therapy (patients with and without exposure to BV prior to ASCT allowed) (cohort 3). Patients were treated with pembrolizumab 200 mg every 3 weeks, and response was assessed every 12 weeks. Preliminary results were reported at the 2016 ASH annual meeting: ORR was 67% (29% CR) in cohort 1, 65% (25% CR) in cohort 2, and 68% (22% CR) in cohort 3, with any degree of reduction in tumor volume from baseline seen in 94% of patients.92 At the time of data presentation, 115 patients had an ongoing response. Reported treatment-related toxicities included pyrexia (11%), hypothyroidism (11%), diarrhea (7%), rash (6%), and nausea (6%).92 Grade 3 treatment-related toxicities included neutropenia (1%), thrombocytopenia (1%), and diarrhea (1%), with no reported treatment-related deaths.92 While these results both in terms of activity and safety are comparable to those reported with nivolumab in the treatment of cHL, it is unknown whether 1 agent has a superior efficacy or safety profile over the other for the treatment of cHL in the absence of a head-to-head clinical trial. On the basis of KEYNOTE 013 and 087 trials discussed above, on March 15, 2017 the US FDA granted accelerated approval to pembrolizumab for the treatment of patients with refractory cHL or patients with cHL who have relapsed after 3 or more prior lines of therapy, making it the second PD-1 inhibitor approved for the treatment of cHL.

Risk in pre- and post- allogeneic SCT

In selected cHL patients with relapsed or refractory disease after ASCT, allogeneic SCT can provide potential durable disease control with similar PFS and OS seen with either myeloablative or reduced intensity conditioning regimens.29,93 PD-1 inhibition has been shown in preclinical models to augment acute GVHD due to T-cell disinhibition, raising concern regarding the safety of checkpoint inhibition in patients who are either being considered for allogeneic SCT or who have relapsed after allogeneic transplant.94,95 Outcomes for 17 cHL patients treated in the phase 1 study (CheckMate 039) and multicohort phase II (CheckMate 205) trials of nivolumab who underwent subsequent allogeneic SCT were reported at the 2016 ASH annual meeting.96 Of the 17 patients treated, there were 6 deaths, all due to non-relapse mortality. Five of the 6 patients died from acute GVHD after undergoing reduced-intensity transplant. Acute GVHD was seen in 82% of patients, most commonly occurring in the skin (12 patients including 4 with grade 4), GI tract (4 with grade 4), and liver (4 with grade 4). Hyperacute GVHD occurring within 14 days of transplant was seen in 2 patients, and 2 patients developed encephalitis, including 1 patient with no infectious cause identified who recovered after treatment with corticosteroids. Hepatic sinusoidal obstruction syndrome was reported in 1 patient who died from multiorgan refractory acute GVHD. The proportion of patients experiencing acute GVHD was higher than expected following allogeneic SCT, including atypical manifestations of GVHD such as apparent autoimmune encephalitis and hyperacute GVHD.96

The largest published experience to date regarding allogeneic SCT following treatment with PD-1-targeting monoclonal antibodies comes from a retrospective study of 39 patients with lymphoma, including 31 patients with cHL, treated with either nivolumab (72%) or pembrolizumab (28%) across multiple studies who went on to receive allogeneic SCT.97 Four of these patients were treated with a combination of a PD-1 inhibitor with ipilimumab, and the remainder received PD-1 inhibitor monotherapy; 49% underwent salvage therapy after treatment with PD-1 inhibitor and before SCT. Of the patients included in the analysis, 38 of 39 underwent reduced intensity conditioning, all underwent T-cell replete transplant, with a median time from last treatment with PD-1 inhibitor to SCT of 62 days.97 Cumulative incidence of grade 3–4 acute GVHD was 23%, including 13% of patients with grade 4 acute GVHD with a median onset of 27 days. Four treatment-related deaths were reported, including 3 patients who died from acute GVHD with onset within 14 days of SCT and 1 patient who died due to sinusoidal obstruction syndrome.97 Seven (18%) patients experienced a prolonged noninfectious febrile syndrome, which was treated with corticosteroids in all cases. Despite these toxicities, the 1-year PFS and OS rates
were 89% and 76%, respectively, with a cumulative incidence of relapse of 14% and nonrelapse mortality of 11%. A higher incidence of acute GVHD (100%) including 1 case of fatal GVHD was seen in patients treated with both ipilimumab and PD-1 inhibition in comparison to those receiving PD-1 inhibitors alone, suggesting a potential increased risk of acute GVHD with combined checkpoint inhibition prior to SCT. Correlative studies showed that, when compared to a matched control cohort, patients treated with PD-1 inhibition prior to SCT had a decreased ratio of CD4+ T-regulatory cells (T-regs) to CD4+ T-cells up to 1 month after transplant, as well as decreased PD-1 expression on T-cells seen up to 6 months after transplant.96 A lower proportion of T-regs has been associated with increased incidence of acute GVHD, but may also result in enhanced graft-versus-lymphoma effect.98 These findings suggest that the immune effects of PD-1 inhibition remain present months after cessation of PD-1 inhibitor therapy, well beyond what would be expected by pharmacokinetic models of drug clearance.97 Clinicians should be aware of the potential risks of the combination of PD-1 blockade followed by allogeneic SCT, but based on experience to date this approach should not be considered contraindicated. More mature data from ongoing and completed trials as well as validation of these findings in a larger cohort of patients will better define the magnitude of the risk for GVHD and the risks and benefits of allogeneic SCT in patients responding to checkpoint inhibition.

Several case reports have demonstrated clinical responses with nivolumab in patients with relapsed cHL following allogeneic SCT, but there has also been 1 case reported of fatal GVHD in a patient treated for relapsed cHL with pembrolizumab who was over 18 months out from transplant.99–105 The results from a retrospective series of 27 patients (26 with cHL) treated at 8 institutions for relapsed lymphoma following allogeneic SCT with either nivolumab or pembrolizumab were reported at the 2016 ASH annual meeting with 10 patients experiencing acute GVHD after treatment, including 3 patients with fatal GVHD.106 The ORR in this series was 79%, including 13 patients with CR. More recently, Herbaux et al107 reported outcomes of 20 patients with relapsed cHL following allo-SCT treated with nivolumab at the standard dose of 3 mg/kg every 2 weeks at medical centers across France. The median patient age was 33; all patients had received prior ASCT and GV. Ten (50%) patients had a history of prior acute GVHD (grade I or II) and 3 (15%) had a history of limited chronic GVHD. All patients were off of immunosuppression for ≥4 weeks prior to treatment initiation. Acute GVHD was seen during the first cycle of treatment in 6 (30%) patients, including 1 patient with febrile multiorgan dysfunction who died within 3 weeks of his first treatment and 3 patients with steroid refractory GVHD which was fatal in 1 of the 3 cases.107 All of these 6 patients had a prior history of acute GVHD. Flare of chronic GVHD was not observed following nivolumab treatment in this cohort of patients. Other toxicities included grade 4 neutropenia and grade 3 thrombocytopenia in 1 patient and grade 2 cerebellar ataxia in a second patient, which required therapy discontinuation in both cases. The ORR was 95%, including a CR rate of 42%. After a median follow-up of 370 days, the 1-year PFS and OS rates were 58.2% and 78.7%, respectively, with 5 relapses reported at last follow-up.107

Interestingly, Raiola et al108 reported an encouraging 3-year PFS and OS rate of 63% and 77%, respectively, in 26 cHL patients treated with nonmyeloablative conditioning regimen followed by a haploidentical SCT and posttransplant high-dose cyclophosphamide for GVHD prophylaxis. The incidence of grade II-IV acute GVHD and of chronic GVHD was 24% and 8%, respectively, suggesting exploration of the potential role of cyclophosphamide in reducing the incidence and the severity of checkpoint-inhibitor induced GVHD through the elimination of allo-reactive T-cells.

Although the high ORR seen in these retrospective series is promising, the risk of severe and treatment-refractory acute GVHD in this setting is a concern warranting further evaluation and prospective study to better quantify the magnitude of this risk and to evaluate treatment options for GVHD in this setting. For patients with cHL relapsing after allogeneic SCT, given the limited options for inducing durable remission, checkpoint blockade is still a consideration with the awareness of the potential for life-threatening GVHD.

**Nivolumab in combination**

Although ORR to nivolumab in cHL has been >60%, the majority of patients achieve PR as best response and a subset of patients progress while on therapy. Whether improved response rates can be achieved with combination therapy is an area of active investigation. At the time of writing, there are 14 clinical trials of nivolumab that include patients with cHL listed on clinicaltrials.gov, 9 of which are open to enrollment (Table 3). We will briefly discuss potential rational combinations of treatment with PD-1 inhibitors including combination with alternate checkpoint inhibitors, combination with cytotoxic chemotherapy, and combination with biologic agents.

Combining multiple checkpoint inhibitors has been shown to be effective in melanoma, where the combination
of nivolumab with the CTLA-4 inhibitor ipilimumab lead to increased response rates, albeit with associated increased toxicity.\(^{81}\) Preliminary results from the CheckMate 039 study of ipilimumab in combination with nivolumab for patients with relapsed/refractory hematologic malignancies were recently presented, with 5 of 65 (8\%) patients discontinuing treatment due to AEs at a median follow-up of 11.4 months; no treatment-related deaths were reported.\(^{111}\) A total of 19 (29\%) patients experienced grade 3 toxicity, with the most commonly reported toxicities of any grade being pyrexia (23\%), fatigue (23\%), and diarrhea (18\%).\(^{109}\) The ORR for the 31 patients with cHL treated with ipilimumab and nivolumab was 74\%, and the rate of CR was 19\%.\(^{109}\) Although the relatively small number of cHL patients limits interpretation of results, the response rates seen in this trial are similar to those seen with nivolumab monotherapy. The hypothesis that the combination of checkpoint inhibitors will improve response rates over a single-agent approach should be tested in future prospective clinical trials, but at the present time there is no evidence to support this approach in cHL.

Combining checkpoint inhibition with conventional chemotherapy is based on the rationale of increasing neo-antigen expression on tumor cells as a consequence of chemotherapy treatment to stimulate a T-cell-mediated antitumor response, which would be further enhanced by the addition of a checkpoint inhibitor.\(^{110}\) However, the potential benefit of this approach may be limited by the immune-suppressive effects of cytotoxic agents. A phase II trial of nivolumab combined with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untreated patients with cHL (NCT02181738, CheckMate205 Arm D) is currently closed to accrual, with results not yet reported as of the time of writing. Future trials are planned examining the safety and efficacy of the combination of nivolumab with cytotoxic chemotherapy in both the frontline setting and for relapsed or refractory disease (NCT03016871 and NCT03004833) that will shed further light on the feasibility and efficacy of this approach.

The combination of BV with nivolumab is of particular interest given the high response rates with both drugs as monotherapy.\(^{25,65}\) Preliminary results from 2 early-phase studies of the combination of BV and nivolumab were recently reported at the 2016 ASH annual meeting.\(^{111,112}\) The first is a phase 1/2 study (NCT02572167) of 25 cHL patients treated with BV dosed at 1.8 mg/kg in combination with nivolumab dosed at 3 mg/kg, both given on day 1, except for cycle 1 where nivolumab was given on day 8, of a 21-day cycle for up to 4 cycles after failure of frontline therapy and prior to ASCT.\(^{111}\) Of the 25 patients enrolled, 16 (64\%) had relapsed and 9 (36\%) had refractory disease after frontline treatment. Toxicity was acceptable, with 3 (15\%) patients experiencing grade 3 toxicity, but no grade 4 toxicity or toxicity leading to discontinuation of treatment reported.\(^{111}\) An increased incidence of infusion reactions were noted with BV and nivolumab when the 2 drugs were administered together, but this was improved with the addition of hydrocortisone and antihistamine premedication. Six patients had completed treatment at the time of the presentation with an ORR of 100\%, including 3 patients with complete metabolic
response.\textsuperscript{111} Results from the phase I ECOG-ACRIN Cancer Research Group E4412 trial with 10 relapsed/refractory cHL patients treated with BV at a dose of 1.2 mg/kg or 1.8 mg/kg combined with nivolumab at a dose of 3 mg/kg given every 21 days for 16 cycles were also reported at the same meeting.\textsuperscript{112} Grade 3 toxicity was observed in 2 of 10 patients including 1 patient treated with BV at a dose of 1.8 mg/kg who discontinued treatment due to grade 3 pneumonitis and grade 3 typhlitis.\textsuperscript{112} No grade 4 toxicities were observed, and the remaining 9 patients were able to complete treatment. Of 8 patients who were evaluable for response at the time of presentation, 5/8 achieved CR and the remaining 3 achieved PR.

Finally, the use of biological agents in combination with PD-1 inhibition is another potential future approach to combination therapy. DNA methyltransferase inhibitors were shown in a preclinical ovarian cancer model to upregulate PD-L1 expression, suggesting a potential role for DNA methyltransferase inhibitors in priming patients for sensitization to checkpoint inhibitor therapy.\textsuperscript{113} In support of this role for epigenetic therapy, in a small single-institution case series of patients treated with either pembrolizumab or nivolumab, 5 cHL patients who were previously treated with azacitidine in combination with romidepsin on a prior clinical trial all achieved a CR to PD-1 inhibitor therapy.\textsuperscript{114} While this higher-than-expected rate of CR is provocative, results from future prospective clinical trials are needed to further evaluate this potential combination therapy.

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica, Phamacyclics, and Janssen) has been successfully employed in the treatment of chronic lymphocytic leukemia as well as subtypes of non-Hodgkin’s lymphoma, including mantle cell lymphoma and Waldenström’s macroglobulinemia.\textsuperscript{115–121} While B-cell non-Hodgkin lymphoma cells exhibit nearly universal BTK expression, BTK expression by RS cells has been reported in only a minority (22%) of cHL biopsy specimens.\textsuperscript{122} Moreover, RS cells lack several components of the B cell receptor signaling pathway, and, to our knowledge, there is no published study that this pathway is constitutively activated in cHL. However, in addition to targeting BTK signaling, ibrutinib has been shown to irreversibly inhibit interleukin-2-inducible kinase (ITK), promoting a shift to Th-1-dominant signaling, thereby enhancing T-cell response to antigenic stimuli.\textsuperscript{123} In a published case report, 2 patients with cHL with relapsed disease following allogeneic SCT were treated with ibrutinib. One achieved a PR with subsequent progression 4 months later, and 1 achieved CR and remained in CR at 6 months follow-up.\textsuperscript{124} In 1 of these patients, expression of interferon-inducible-protein 10 was reported in serum samples after treatment, suggesting shift to Th-1 signaling and a potential immune modulatory effect of ibrutinib mediated by its activity on ITK.\textsuperscript{124} The hypothesis that ibrutinib may enhance the immune effect of checkpoint inhibition in cHL warrants exploration in clinical trials, with a current phase II trial open to enrollment (NCT 02940301).

At this time, until results from these and future studies are available, the use of nivolumab in combination with other agents for the treatment of cHL remains investigational.

**Patient-focused perspectives**

As discussed previously, the side effects seen to this point with nivolumab in clinical practice are distinct from the side effect profile seen with cytotoxic agents that remain the mainstay of treatment for patients with cHL in the frontline setting and at first disease relapse. The long-term effects of PD-1 blockade are unknown, and this as well as the durability of response will be an important question for patients as outcomes mature.

Given the wide therapeutic index seen in trials utilizing nivolumab in other disease groups, 1 question for patients is the necessity of an every 2 week dosing schedule. As discussed previously, the elimination half-life of nivolumab is 26.7 days, and ongoing prospective trials of combination therapy with nivolumab in cHL and other diseases are utilizing an every 3-week dosing schedule. As patients with clinical response to nivolumab may remain on therapy for months and even years, the question of whether the dosing schedule can be switched to an every 3-week schedule and whether nivolumab can be safely stopped at any point is relevant to the quality of life for patients benefitting from this therapy. Results from ongoing prospective trials with nivolumab will help in answering this important question in the coming years.

**Conclusion and future directions**

Nivolumab has demonstrated impressive response rates and in some cases durable remissions in patients with cHL. Given the excellent response rates and acceptable side effect profile, nivolumab received FDA approval for cHL patients who have progressed following both prior ASCT and BV therapy. The long-term durability of response and the magnitude of benefit and risk of allogeneic SCT in patients who have responded to nivolumab will be better elucidated with long-term follow-up from completed trials of nivolumab monotherapy and potential future prospective investigation. Preliminary results suggest that administration of pembrolizumab results in similarly impressive responses in this patient population; whether a clinical meaningful difference between these 2 PD-1 inhibitors exists would be best answered in a phase III, head-to-head clinical trial.
Given the high response rates seen with nivolumab, whether it can be incorporated into earlier lines of therapy remains to be seen in future trials, including ongoing trials of the combination of nivolumab with AVD chemotherapy in untreated patients (NCT 02181738) and the combination of nivolumab with BV in patients aged ≥ 60 years (NCT 27758717). Incorporating nivolumab into earlier lines of therapy offers the potential to reduce exposure to cytotoxic therapy and the associated risks and toxicities and abrogates the potential immunosuppressive effect of prior lines of therapy. While the ultimate role of nivolumab in the treatment of cHL remains to be seen, it is already an established part of treatment in the relapsed and refractory setting and represents a success story in the rational application of genomic-guided cancer therapy.

Author contributions
DAB and LA contributed toward literature review, analysis, drafting, and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Ansell SM. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. Am J Hematol. 2016;91(1):109–112.
2. Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):653–662.
3. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519). J Clin Oncol. 2005;23(36):9208–9218.
4. Hoskin PJ, Lowry L, Horwitz A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009;27(32):5390–5396.
5. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin’s lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–691.
6. Engert A, Dhiel V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(2):4548–4554.
7. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601–3608.
8. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634–4642.
9. Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234–4242.
10. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–652.
11. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607.
12. Advani RH, Hong F, Fisher RI, et al. Randomized phase III trial comparing ABVD plus radiotherapy with the stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015;33(17):1936–1942.
13. Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin lymphoma: results of the phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016;34(17):2028–2036.
14. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212.
15. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD vs BEACOPP vs COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–1181.
16. Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (EPS 0-2) of the LYSIA H34 randomized trial. Ann Oncol. 2014;25(8):1622–1628.
17. Vassilakopoulos TP, Johnson PW. Treatment of advanced-stage Hodgkin’s lymphoma. Semin Hematol. 2016;53(3):171–179.
18. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89(3):801–813.
19. Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106(4):1473–1478.
20. Gerrie AS, Power MM, Shepherd JD, Savage KJ, Sehn LH, Connors JM. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Ann Oncol. 2014;25(11):2218–2223.
21. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet. 1993;341(8852):1051–1054.
22. Chopra R, McMullan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease: a single-center eight-year study of 155 patients. Blood. 1999;93(8):1137–1145.
23. Schmitt N, Pilstner B, Sesto M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomized trial. Lancet. 2002;359(9323):2065–2071.
24. Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010;28(34):5074–5080.
25. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
26. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. *Blood*. 2015;125(8):1236–1243.

27. Moskowitz CH, Nademane A, Massi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015;385(9980):1853–1862.

28. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma. *Bone Marrow Transplant*. 2003;32(7):673–679.

29. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. 2008;26(3):455–462.

30. Hertzberg M. Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT? *Hematol Oncol Clin North Am*. 2014;28(1):123–147.

31. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. *Bone Marrow Transplant*. 2008;41(9):765–770.

32. Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin’s lymphoma. *Br J Haematol*. 2011;152(3):261–272.

33. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. *Ann Oncol*. 2007;18(6):1071–1079.

34. Aparicio J, Segura A, Garcia S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. *Ann Oncol*. 1999;10(5):593–595.

35. Zelenetz AD, Hamlin P, Kewalramani T, Yalaham J, Nimer S, Moskowitz CH. Iosifamid, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. *Ann Oncol*. 2003;14(Suppl 1):i5–i10.

36. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. *J Clin Oncol*. 2000;18(3):2615–2619.

37. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. *Haematologia*. 2000;85(9):926–929.

38. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar Bond and Alinari. 2012;84(3):e329–e335.

39. Moskowitz CH, Nademane A, Massi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015;385(9980):1853–1862.

40. Fehninger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood*. 2011;118(19):5119–5125.

41. Johnstone PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. *Am J Hematol*. 2010;85(5):320–324.

42. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. *J Clin Oncol*. 2012;30(18):2197–2203.

43. Steidl C, Ciborows J, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. *J Clin Oncol*. 2011;29(14):1812–1826.

44. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. *Nat Immunol*. 2007;8(3):239–245.

45. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med*. 2000;192(7):1027–1034.

46. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat Med*. 1999;5(12):1365–1369.

47. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. *Nat Immunol*. 2001;2(3):261–268.

48. Park JJ, Omiya R, Matsunuma Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. *Biol. 2010;116(8):1291–1298.

49. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*. 2002;8(8):793–800.

50. Rosenberg W, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med*. 2003;198(6):851–862.

51. Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. *J Clin Oncol*. 2016;34(23):2690–2697.

52. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood*. 2010;116(17):3268–3277.

53. Hoos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. *Blood*. 1996;87(4):1571–1578.

54. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. *Genes Chromosomes Cancer*. 2001;30(4):393–401.

55. Hoos S, Kupper M, Ohi S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD53+ Hodgkin cells. *Cancer Res*. 2000;60(3):549–552.

56. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. *Blood*. 2003;102(12):3871–3879.

57. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature*. 2011;471(7388):377–381.

58. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. *N Engl J Med*. 2015;372(4):311–319.
65. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
66. Kuppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;(1):491–496.
67. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175.
68. Topalian SL, Holland FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
69. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
70. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
71. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
72. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti–CTLA-4 treatment (Checkmate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
73. US Food and Drug Administration. Modification of the Dose Regimen for Nivolumab. Silver Spring, MD: US Food and Drug Administration; 2016.
74. Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016;27(11):1982–1992.
75. Agrawal S, Statkevich P, Bajaj G, et al. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Oncol. 2015;33(18):1889–1899.
76. Ansell S. Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma: results of an international phase II trial. J Clin Oncol. 2011;29(4):991–993.
77. Timmerman J, Engert A, Younes A. Checkmate 205 update with mini-12 month follow up: A phase 2 study of Nivolumab in patients with relapsed/refractory Hodgkin lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation. Int J Hematol. 2017;105(3):383–386.
78. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755.
79. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265–268.
80. Wilgenhof S, Neyns B. Anti–CTLA-4 antibody-induced Guillain–Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–993.
81. Loochta AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52(2):307–308.
82. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
83. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance modification of the Dose Regimen for Nivolumab. 2015;373(18):1749–1755.
84. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
85. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755.
86. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265–268.
87. Wilgenhof S, Neyns B. Anti–CTLA-4 antibody-induced Guillain–Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–993.
88. Loochta AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52(2):307–308.
89. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
90. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in Melanoma. Clin Ther. 2015;37(4):764–782.
91. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739.
92. Moskowitz A, Zinzani PL. Female M. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood. 2016;128: abstract 1107; American Society of Hematology Annual Meeting.
93. Alinari L, Blum KA. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant. Blood. 2016;127(3):287–295.
94. Blazar BR, Carreno BM. Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272–1277.
95. Armand P, Zinzani PL, Collins G. Outcomes of Allogeneic Hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2017;129(10):1380–1388.
96. Fujioka T, Tamaki H, Iikegami K, et al. Frequency of CD4(+)/FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2013;48(6):859–864.
97. Villasboas JC, Ansell SM, Witzig TE. Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(6):850–852.
98. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side effects of anti–PD-1 therapy. J Cancer. 2016;54:139–148.
99. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982.
100. Larkin J, Chiarion-Silieri V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34.
101. Angenendt L, Schliemann C, Lutz M, et al. Nivolumab in a patient with progressive disease after both autologous and allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52(3):754–755.
105. Godfrey J, Bishop MR, Syed S, Hyjek E, Kline J. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. *J Immunother Cancer*. 2017;5:11.

106. Haverkos BM, Schowinsky J, Kaplan J. Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. *Blood*. 2016;128: abstract 1163; American Society of Hematology. Annual Meeting.

107. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin’s lymphoma. *Blood*. Epub 2017 Mar 7.

108. Raiola A, Dominietto A, Valardo R, et al. Unmanipulated haploidentical BMT following non-myoelobative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. *Bone Marrow Transplant*. 2014;49(2):190–194.

109. Ansell S, Gutierrez M, Shipp M. A Phase I Study of Nivolumab in Combination with Iplimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 059). Presented at: American Society of Hematology Annual Meeting; December 3–6; 2016; San Diego, CA; abstract 183.

110. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. *Cell*. 2015;161(2):205–214.

111. Herrera AF, Bartlett N, Ramchandren R. Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Presented at: American Society of Hematology Annual Meeting; December 3–6; 2016; San Diego, CA; abstract 1105.

112. Diefenbach C, Hong F, David KA. A Phase I Study with an Expansion Cohort of the Combination of Iplimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). Presented at: American Society of Hematology Annual Meeting; December 3–6; 2016; San Diego, CA; abstract 1106.

113. Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. *Cell*. 2015;162(5):974–986.

114. Falchi L, Sawas A, Deng C, et al. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. *J Hematol Oncol*. 2016;9(1):132.

115. Coutre SE, Furman RR, Finn JW, et al. Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. *Clin Cancer Res*. 2017;23(5):1149–1155.

116. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. *Blood*. 2015;126(6):739–745.

117. Maddocks K, Blum KA. Ibrutinib in B-cell lymphomas. *Curr Treat Options Oncol*. 2014;15(2):226–237.

118. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med*. 2013;369(1):32–42.

119. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*. 2013;369(6):507–516.

120. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in waldenstrom’s macroglobulinemia. *N Engl J Med*. 2015;373(6):584–586.

121. Teon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. *N Engl J Med*. 2015;373(15):1430–1440.

122. Fernandez-Vega I, Quiros LM, Santos-Juanes J, Pane-Foro M, Marafioti T. Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. *Virchows Arch*. 2015;466(2):229–235.

123. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*. 2013;122(15):2539–2549.

124. Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in refractory classic Hodgkin’s lymphoma. *N Engl J Med*. 2015;373(14):1381–1382.